Moberg Pharma ABFRA:MB8 +2.28%59 Days Payable is 158.36 as of Mar. 2026, which is 172% above its 10-year median of 58.19. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, Moberg Pharma AB ranks better than 85.76% on this metric.
The historical rank and industry rank for Moberg Pharma AB's Days Payable or its related term are showing as below:
FRA:MB8'
s Days Payable Range Over the Past 10 Years
Min: 42.27 Med: 58.19 Max: 570.68
Current: 208.06
During the past 13 years, Moberg Pharma AB's highest Days Payable was 570.68. The lowest was 42.27. And the median was 58.19.
FRA:MB8's Days Payable is ranked better than 85.76% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:MB8: 208.06
Moberg Pharma AB's Days Payable
declined
from Mar. 2025 (277.58) to Mar. 2026 (158.36).
It may suggest that Moberg Pharma ABaccelerated paying its suppliers.
Moberg Pharma AB Days Payable Related Terms
Moberg Pharma AB Days Payable Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Moberg Pharma AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (FRA:MB8) has a Days Payable of 158.36 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Moberg Pharma AB and its competitors. This is 172% above median its historical median of 58.19. Over the past decade, Moberg Pharma AB's Days Payable has ranged from 42.27 to 570.68. According to the industry distribution chart, Moberg Pharma AB ranks #131 out of 920 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Moberg Pharma AB's Days Payable too high?
Moberg Pharma AB's current Days Payable of 158.36 is 172% above median its 10-year median of 58.19. Over the past 10 years, this metric has ranged from a low of 42.27 to a high of 570.68. The Drug Manufacturers industry median Days Payable is 90.84. Moberg Pharma AB's value of 158.36 is 74.3% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #131 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #131 out of 920 companies for Days Payable. This places Moberg Pharma AB in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Moberg Pharma AB's value of 158.36 is 74.3% above this benchmark. Historically, Moberg Pharma AB's own Days Payable has ranged from 42.27 to 570.68 over the past decade. While the company's 10-year median is 58.19 vs. the industry median of 90.84, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Days Payable of 158.36 is 74.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Days Payable is 158.36, which is 172% above median its own 10-year median of 58.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Days Payable of 158.36. The stock's GF Value™ is €1.07, compared to a current price of €0.81 — trading 24.6% below its estimated fair value. The current Days Payable is 158.36, which is 172% above median its 10-year median of 58.19 and 74.3% above the Drug Manufacturers industry median of 90.84. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Days Payable is 158.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.81 is trading 24.6% below its estimated GF Value™ of €1.07.
Key valuation signals for FRA:MB8:
Days Payable: 158.36 (172% above median its 10-year median of 58.19)
GF Value™: €1.07 vs. price of €0.81 (24.6% below fair value)
Industry Position: 74.3% above the Drug Manufacturers median (#131 of 920)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
